Treatment and follow-up of patients with malignant haemopathies, febrile neutropaenia and tranfusions-at-risk

Bone marrow and haematopoietic stem cell transplantations in collaboration with the Hôpital Universitaire des Enfants Reine Fabiola: classical autologous and allogeneic, non myeloablative (for patients up to the age of 70); haploidentical; and cord blood

Isolation of patients with neutropaenia or aplasia

Development of new haematopoietic approaches (e.g., experimental transplantations, regenerative cellular therapies, extracorporeal photopheresis)

FielD, technologies anD MethoDs


Our dreams of yesterday have become today’s reality: as research advances, the disease retreats. PrOF DOMinique brOn, Head of the Haemato-Oncology & transplantation Department

Main areas Malignant haemopathies Management of febrile neutropaenia

Haematopoietic stem cell transplantations

Cellular therapies and regenerative medicine

aPPlieD research Translational research, in particular an important study designed to better define prognostic factors of chronic lymphocytic leukaemia and, ultimately, to provide better therapies for patients.

Cellular (and regenerative) therapy using mesenchymal stromal cells, isolated from bone marrow, cord blood and adipose tissue. These cells have the potential to accelerate haematological engraftment, to limit post-transplantation immune reactions, and to regenerate bone, adipose or muscular tissues.

Stem cell transplantation, including the development of new transplantation tech- niques (e.g., double cord blood, haplo-identical).